EClinicalMedicine 润色咨询

EClinicalMedicine

出版年份：暂无数据 年文章数：800 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065686, encodeId=a75a10656860b, content=偏重的研究方向：肿瘤<br>经验分享：这个杂志接受后会不会有编辑润色？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ba2426608, createdName=遗忘爱神, createdTime=Mon Nov 01 08:11:43 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001378, encodeId=317210013e878, content=这个杂志收生信和基础类文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Wed Jul 21 12:57:02 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968379, encodeId=c3b69683e989, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=254e2066521, createdName=HONGGE, createdTime=Tue May 25 15:42:46 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.<br>这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805030, encodeId=2f2880503089, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0<br>经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。<br>另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Wed Jul 29 10:28:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805927, encodeId=bc9280592efc, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：新杂志，命中率还可以吧应该, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d862240300, createdName=12141b7fm46(暂无昵称), createdTime=Mon Aug 03 15:32:06 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2022-03-03 Relivenus

    还可以

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065686, encodeId=a75a10656860b, content=偏重的研究方向：肿瘤<br>经验分享：这个杂志接受后会不会有编辑润色？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ba2426608, createdName=遗忘爱神, createdTime=Mon Nov 01 08:11:43 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001378, encodeId=317210013e878, content=这个杂志收生信和基础类文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Wed Jul 21 12:57:02 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968379, encodeId=c3b69683e989, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=254e2066521, createdName=HONGGE, createdTime=Tue May 25 15:42:46 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.<br>这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805030, encodeId=2f2880503089, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0<br>经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。<br>另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Wed Jul 29 10:28:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805927, encodeId=bc9280592efc, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：新杂志，命中率还可以吧应该, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d862240300, createdName=12141b7fm46(暂无昵称), createdTime=Mon Aug 03 15:32:06 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2021-12-29 桑晒麦拉

    撰写文章题目有没有技巧？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065686, encodeId=a75a10656860b, content=偏重的研究方向：肿瘤<br>经验分享：这个杂志接受后会不会有编辑润色？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ba2426608, createdName=遗忘爱神, createdTime=Mon Nov 01 08:11:43 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001378, encodeId=317210013e878, content=这个杂志收生信和基础类文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Wed Jul 21 12:57:02 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968379, encodeId=c3b69683e989, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=254e2066521, createdName=HONGGE, createdTime=Tue May 25 15:42:46 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.<br>这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805030, encodeId=2f2880503089, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0<br>经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。<br>另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Wed Jul 29 10:28:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805927, encodeId=bc9280592efc, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：新杂志，命中率还可以吧应该, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d862240300, createdName=12141b7fm46(暂无昵称), createdTime=Mon Aug 03 15:32:06 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2021-12-28 ms6000000264964247

    文章题目怎么写更好？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065686, encodeId=a75a10656860b, content=偏重的研究方向：肿瘤<br>经验分享：这个杂志接受后会不会有编辑润色？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ba2426608, createdName=遗忘爱神, createdTime=Mon Nov 01 08:11:43 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001378, encodeId=317210013e878, content=这个杂志收生信和基础类文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Wed Jul 21 12:57:02 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968379, encodeId=c3b69683e989, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=254e2066521, createdName=HONGGE, createdTime=Tue May 25 15:42:46 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.<br>这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805030, encodeId=2f2880503089, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0<br>经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。<br>另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Wed Jul 29 10:28:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805927, encodeId=bc9280592efc, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：新杂志，命中率还可以吧应该, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d862240300, createdName=12141b7fm46(暂无昵称), createdTime=Mon Aug 03 15:32:06 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2021-11-01 遗忘爱神

    偏重的研究方向：肿瘤
    经验分享：这个杂志接受后会不会有编辑润色？

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065686, encodeId=a75a10656860b, content=偏重的研究方向：肿瘤<br>经验分享：这个杂志接受后会不会有编辑润色？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ba2426608, createdName=遗忘爱神, createdTime=Mon Nov 01 08:11:43 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001378, encodeId=317210013e878, content=这个杂志收生信和基础类文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Wed Jul 21 12:57:02 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968379, encodeId=c3b69683e989, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=254e2066521, createdName=HONGGE, createdTime=Tue May 25 15:42:46 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.<br>这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805030, encodeId=2f2880503089, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0<br>经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。<br>另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Wed Jul 29 10:28:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805927, encodeId=bc9280592efc, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：新杂志，命中率还可以吧应该, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d862240300, createdName=12141b7fm46(暂无昵称), createdTime=Mon Aug 03 15:32:06 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2021-07-21 malonglee

    这个杂志收生信和基础类文章吗？

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065686, encodeId=a75a10656860b, content=偏重的研究方向：肿瘤<br>经验分享：这个杂志接受后会不会有编辑润色？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ba2426608, createdName=遗忘爱神, createdTime=Mon Nov 01 08:11:43 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001378, encodeId=317210013e878, content=这个杂志收生信和基础类文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Wed Jul 21 12:57:02 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968379, encodeId=c3b69683e989, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=254e2066521, createdName=HONGGE, createdTime=Tue May 25 15:42:46 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.<br>这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805030, encodeId=2f2880503089, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0<br>经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。<br>另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Wed Jul 29 10:28:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805927, encodeId=bc9280592efc, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：新杂志，命中率还可以吧应该, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d862240300, createdName=12141b7fm46(暂无昵称), createdTime=Mon Aug 03 15:32:06 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2021-05-25 HONGGE

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。

    6

    展开6条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065686, encodeId=a75a10656860b, content=偏重的研究方向：肿瘤<br>经验分享：这个杂志接受后会不会有编辑润色？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ba2426608, createdName=遗忘爱神, createdTime=Mon Nov 01 08:11:43 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001378, encodeId=317210013e878, content=这个杂志收生信和基础类文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Wed Jul 21 12:57:02 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968379, encodeId=c3b69683e989, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=254e2066521, createdName=HONGGE, createdTime=Tue May 25 15:42:46 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.<br>这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805030, encodeId=2f2880503089, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0<br>经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。<br>另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Wed Jul 29 10:28:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805927, encodeId=bc9280592efc, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：新杂志，命中率还可以吧应该, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d862240300, createdName=12141b7fm46(暂无昵称), createdTime=Mon Aug 03 15:32:06 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2021-05-10 dangjunsy

    EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.
    这是该杂志官方首页上写的

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065686, encodeId=a75a10656860b, content=偏重的研究方向：肿瘤<br>经验分享：这个杂志接受后会不会有编辑润色？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ba2426608, createdName=遗忘爱神, createdTime=Mon Nov 01 08:11:43 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001378, encodeId=317210013e878, content=这个杂志收生信和基础类文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Wed Jul 21 12:57:02 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968379, encodeId=c3b69683e989, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=254e2066521, createdName=HONGGE, createdTime=Tue May 25 15:42:46 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.<br>这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805030, encodeId=2f2880503089, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0<br>经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。<br>另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Wed Jul 29 10:28:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805927, encodeId=bc9280592efc, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：新杂志，命中率还可以吧应该, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d862240300, createdName=12141b7fm46(暂无昵称), createdTime=Mon Aug 03 15:32:06 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2020-07-29 doctor0805

    审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0
    经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。
    另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065686, encodeId=a75a10656860b, content=偏重的研究方向：肿瘤<br>经验分享：这个杂志接受后会不会有编辑润色？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85ba2426608, createdName=遗忘爱神, createdTime=Mon Nov 01 08:11:43 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001378, encodeId=317210013e878, content=这个杂志收生信和基础类文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Wed Jul 21 12:57:02 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968379, encodeId=c3b69683e989, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：和doctor0805，一样的经历。投lancet oncology，拒稿后推荐到ECM，免除版面费，心有不甘，再投JAMA Oncol，仍然被拒。然后接受transfer到ECM。一审25天左右，5个审稿人，二审再一个月。4月刚被SCIE收录，明年出首个IF，预计9份左右，上10有点难。期刊名字没取好，如果加个Lancet就不一样了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=254e2066521, createdName=HONGGE, createdTime=Tue May 25 15:42:46 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.<br>这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805030, encodeId=2f2880503089, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:3500.0<br>经验分享：本来投了篇lancet oncology，后来人家拒稿后推荐到ECM，心有不甘，再投JAMA Oncol，仍然被拒。其实我觉着完全有机会再试一试10分左右的杂志，但是这个热点过了就真过了，迅速投了ECM。6月投，7月底接收，就major revision了一次，然后连minor revision都没有就被接受了。接收后没有太多喜悦，毕竟预期10分的，本来预期是投三次，不行再转投ECM，所以才试了JAMA，最后竟然试了两次就不试其他杂志了，心太大了，浪费了一次好机会。<br>另外一个想吐槽的就是，版面费太贵了，两万多软妹币！恰逢国家正在改革，医院对两万以上的版面费要求作者给出必要性说明，这个真不好说呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad11919081, createdName=doctor0805, createdTime=Wed Jul 29 10:28:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805927, encodeId=bc9280592efc, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：新杂志，命中率还可以吧应该, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d862240300, createdName=12141b7fm46(暂无昵称), createdTime=Mon Aug 03 15:32:06 CST 2020, time=2020-08-03, status=1, ipAttribution=)]
    2020-08-03 12141b7fm46(暂无昵称)

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享：新杂志，命中率还可以吧应该

    0

共117条页码: 3/12页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分